Anastrozole versus tamoxifen as first-line therapy in postmenopausal patients with hormone-dependent advanced breast cancer: A prospective, randomized, phase III studyMILLA-SANTOS, Alfredo; MILLA, Lidon; PORTELLA, Jordi et al.American journal of clinical oncology. 2003, Vol 26, Num 3, pp 317-322, issn 0277-3732, 6 p.Article

Paclitaxel, carboplatin, and topotecan in the treatment of patients with small cell lung carcinoma: A Phase II trial of the minnie pearl cancer research networkHAINSWORTH, John D; MORRISSEY, Lisa H; SCULLIN, Daniel C et al.Cancer. 2002, Vol 94, Num 9, pp 2426-2433, issn 0008-543XArticle

Paclitaxel/carboplatin as first-line chemotherapy in advanced ovarian cancer : Efficacy and adverse effects with special consideration of peripheral neurotoxicityMAYERHOFER, Klaus; BODNER-ADLER, Barbara; BODNER, Klaus et al.Anticancer research. 2000, Vol 20, Num 5C, pp 4047-4050, issn 0250-7005Article

Malignant mesothelioma: New insights into a rare diseaseREMON, Jordi; LIANES, Pilar; MARTINEZ, Susana et al.Cancer treatment reviews. 2013, Vol 39, Num 6, pp 584-591, issn 0305-7372, 8 p.Article

Multicentre phase II study using increasing doses of irinotecan combined with a simplified LV5FU2 regimen in metastatic colorectal cancerDUFFOUR, Jacqueline; GOURGOU, Sophie; DESSEIGNE, Francoise et al.Cancer chemotherapy and pharmacology. 2007, Vol 60, Num 3, pp 383-389, issn 0344-5704, 7 p.Article

First-line treatment with irinotecan and raltitrexed in metastatic colorectal cancer : Mature results of a multicenter phase II studyAPARICIO, Jorge; VICENT, José M; MIQUEL, Balcells et al.Oncology. 2005, Vol 68, Num 1, pp 58-63, issn 0030-2414, 6 p.Article

A randomized, multicenter prospective trial assessing long-acting release octreotide pamoate plus tamoxifen as a first line therapy for advanced breast carcinomaBAJETTA, Emilio; PROCOPIO, Giuseppe; FERRARI, Leonardo et al.Cancer. 2002, Vol 94, Num 2, pp 299-304, issn 0008-543XArticle

Phase I study of docetaxel in combination with cyclophosphamide as first-line chemotherapy for metastatic breast cancerVASEY, P. A; ROCHE, H; BISSET, D et al.British journal of cancer. 2002, Vol 87, Num 10, pp 1072-1078, issn 0007-0920, 7 p.Article

A phase I clinical and pharmacokinetic study evaluating vinflunine in combination with epirubicin as first-line treatment in metastatic breast cancerCHAN, S; CAMPONE, M; SANTORO, A et al.Cancer chemotherapy and pharmacology. 2014, Vol 73, Num 5, pp 903-910, issn 0344-5704, 8 p.Article

A multi-center phase II study of S-1 plus paclitaxel as first-line therapy for patients with advanced or recurrent unresectable gastric cancerJAE JIN LEE; KIM, Si-Young; CHOI, Jin-Hyuk et al.Cancer chemotherapy and pharmacology. 2009, Vol 63, Num 6, pp 1083-1090, issn 0344-5704, 8 p.Article

Two-weekly gemcitabine fixed dose rate and oxaliplatin combination chemotherapy for advanced non-small-cell lung cancerFRÜH, M; GILLESSEN, S; CERNY, T et al.Lung cancer. 2008, Vol 62, Num 3, pp 344-350, issn 0169-5002, 7 p.Article

Phase II multicentre study of docetaxel plus cisplatin in patients with advanced urothelial cancerGARCIA DEL MURO, X; MARCUELLO, E; GUMA, J et al.British journal of cancer. 2002, Vol 86, Num 3, pp 326-330, issn 0007-0920Article

Treatment of Primary FSGS in AdultsKORBET, Stephen M.Journal of the American Society of Nephrology. 2012, Vol 23, Num 11, pp 1769-1776, issn 1046-6673, 8 p.Article

Functional Decline in Older Patients With Cancer Receiving First-Line ChemotherapyHOPPE, Stéphanie; RAINFRAY, Muriel; VOGT, Luc et al.Journal of clinical oncology. 2013, Vol 31, Num 31, pp 3877-3882, issn 0732-183X, 6 p.Article

First-Line Chemotherapy of Disseminated Germ Cell TumorsNICHOLS, Craig; KOLLMANNSBERGER, Christian.Hematology/oncology clinics of North America. 2011, Vol 25, Num 3, issn 0889-8588, viii, 543-556 [15 p.]Article

Immunoglobulin treatment in primary antibody deficiencyMAARSCHALK-ELLERBROEK, L. J; HOEPELMAN, I. M; ELLERBROEK, P. M et al.International journal of antimicrobial agents (Print). 2011, Vol 37, Num 5, pp 396-404, issn 0924-8579, 9 p.Article

Carboplatin and Paclitaxel versus Cisplatin, Paclitaxel and Doxorubicin for first-line chemotherapy of Advanced Ovarian Cancer : A Hellenic Cooperative Oncology Group (HeCOG) studyARAVANTINOS, Gerasimos; FOUNTZILAS, George; BRIASOULIS, Euangelos et al.European journal of cancer (1990). 2008, Vol 44, Num 15, pp 2169-2177, issn 0959-8049, 9 p.Article

Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European organization for research and treatment of cancer 10961 multicenter phase III trialBIGANZOLI, L; CUFER, T; LOHRISCH, C et al.Journal of clinical oncology. 2002, Vol 20, Num 14, pp 3114-3121, issn 0732-183XArticle

Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphomaGISSELBRECHT, Christian; LEPAGE, Eric; HERMINE, Olivier et al.Journal of clinical oncology. 2002, Vol 20, Num 10, pp 2472-2479, issn 0732-183XArticle

Perspectives and opportunities: Docetaxel in the current and future treatment of non-small cell lung cancerGREEN, Mark R.Seminars in oncology. 2002, Vol 29, Num 3, pp 17-21, issn 0093-7754, SUP12Article

Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma : Results of two randomized trials designed for combined analysisBONNETERRE, Jacques; BUZDAR, Aman; NABHOLTZ, Jean-Marc A et al.Cancer. 2001, Vol 92, Num 9, pp 2247-2258, issn 0008-543XArticle

Marimastat as first-line therapy for patients with unresectable pancreatic cancer : a randomized trialBRAMHALL, S. R; ROSEMURGY, A; BROWN, P. D et al.Journal of clinical oncology. 2001, Vol 19, Num 15, pp 3447-3455, issn 0732-183XArticle

Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women : Results of a North American multicenter randomized trialNABHOLTZ, J. M; BUZDAR, A; POLLAK, M et al.Journal of clinical oncology. 2000, Vol 18, Num 22, pp 3758-3767, issn 0732-183XArticle

A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC)GOTO, Koichi; NISHIO, Makoto; FUKUYAMA, Tamaki et al.Lung cancer. 2013, Vol 82, Num 1, pp 109-114, issn 0169-5002, 6 p.Article

Is there a standard regimen for first-line treatment of advanced/metastatic Non-Small-Cell Lung Cancer? What has meta-analyses contributed to today's standard of carePALLIS, Athanasios G; GEORGOULIAS, Vassilis.Lung cancer. 2012, Vol 75, Num 3, pp 269-274, issn 0169-5002, 6 p.Article